. Drv/rtv, One additional patient (2.3%) was simplified to a PI monotherapy in the VSG. Among patients who had treatment simplification to dual or monotherapy (n=56), 51 (96.2%) were virologically suppressed at the last follow-up. HIV-1 RNA level was between 51 and 200 copies/mL in 2 patients (3.9%) in the VFG and measurement was missing for 3 (data not shown)

, Dernières statistiques sur l'état de l'épidémie de sida

D. Sur,

. Invs, Bulletin de santé publique infection à VIH

D. Sur,

G. Maartens, C. Celum, and S. R. Lewin, HIV infection: epidemiology, pathogenesis, treatment, and prevention, Lancet Lond Engl, vol.384, pp.258-71, 2014.

B. Larder, G. Darby, and D. Richman, HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy, Science, vol.243, pp.1731-1735, 1989.

P. Kellam, C. A. Boucher, and B. A. Larder, Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine, Proc Natl Acad Sci, vol.89, pp.1934-1942, 1992.

J. D. Roberts, K. Bebenek, and T. A. Kunkel, The accuracy of reverse transcriptase from HIV-1, Science, vol.242, pp.1171-1174, 1988.

K. Metzner, Impact of HIV minor species and tropism, Retrovirology, 2012.

D. Sur,

C. Delaugerre, M. Chaix, J. Warszawski, C. Rouzioux, and S. Blanche, La résistance du VIH-1 aux antirétroviraux chez les enfants infectés : du nouveau-né à l'adolescent, Arch Pédiatrie, vol.14, pp.298-302, 2007.

R. W. Shafer, S. Rhee, D. Pillay, V. Miller, P. Sandstrom et al., HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance, AIDS, vol.21, pp.215-238, 2007.

D. M. Tebit, H. Patel, A. Ratcliff, E. Alessandri, J. Liu et al., HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs, AIDS Res Hum Retroviruses, vol.32, pp.676-88, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02442657

M. Witvrouw, C. Pannecouque, W. M. Switzer, T. M. Folks, D. Clercq et al., Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis, Antivir Ther, vol.9, pp.57-65, 2004.

A. Blanc, F. Bonnet, F. Brun-vezinet, D. Costagliola, F. Dabis et al., Groupe d'experts pour la prise en charge du VIH, vol.15, 2016.

M. Chaix, M. Grude, H. Delagrèverie, C. Roussel, H. Pere et al., High prevalence of NNRTI and INI-resistant polymorphic virus in primary HIV infection

D. Descamps, L. Assoumou, M. Chaix, A. Chaillon, S. Pakianather et al., National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade, J Antimicrob Chemother, vol.68, pp.2626-2657, 2001.
URL : https://hal.archives-ouvertes.fr/hal-01101110

L. Assoumou, L. Bocket, C. Pallier, M. Grude, R. Ait-namane et al., Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France, J Antimicrob Chemother, vol.74, pp.1417-1441, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02154058

T. Davy, L. Brunet, S. Napravnik, O. Zakharova, A. M. Dennis et al., Low prevalence of HIV drug resistance with modern agents

L. Assoumou, C. Charpentier, P. Recordon-pinson, M. Grudé, C. Pallier et al., Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study, J Antimicrob Chemother, vol.72, pp.1769-73, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01882314

B. A. Larder and S. D. Kemp, Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT), Science, vol.246, pp.1155-1163, 1989.

D. Arion, N. Kaushik, S. Mccormick, G. Borkow, and M. A. Parniak, Phenotypic Mechanism of HIV-1 Resistance to 3'-Azido-3'-deoxythymidine (AZT): Increased Polymerization Processivity and Enhanced Sensitivity to Pyrophosphate of the Mutant Viral Reverse Transcriptase, Biochemistry, vol.37, pp.15908-15925, 1998.

R. W. Shafer, R. Kantor, and M. J. Gonzales, The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors, AIDS Rev, vol.2, pp.211-239, 2000.

A. M. Wensing, V. Calvez, F. Ceccherini-silberstein, C. Charpentier, H. F. Günthard et al., Update of the Drug Resistance Mutations in HIV-2019, vol.27, p.11, 2019.

H. Xu, E. L. Asahchop, M. Oliveira, P. K. Quashie, Y. Quan et al., Compensation by the E138K Mutation in HIV-1 Reverse Transcriptase for Deficits in Viral Replication Capacity and Enzyme Processivity Associated with the M184I/V Mutations, J Virol, vol.85, pp.11300-11308, 2011.

U. M. Parikh, L. Bacheler, D. Koontz, and J. W. Mellors, The K65R Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Exhibits Bidirectional Phenotypic Antagonism with Thymidine Analog Mutations, J Virol, vol.80, pp.4971-4978, 2006.

J. L. Mbisa, R. K. Gupta, D. Kabamba, V. Mulenga, M. Kalumbi et al., The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains, Retrovirology, vol.8, p.31, 2011.

. Ias-usa, Update of the Drug Resistance Mutations in HIV-1, 2017.

D. Sur,

M. Wirden, B. Roquebert, A. Derache, A. Simon, C. Duvivier et al., Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients, Antimicrob Agents Chemother, vol.50, pp.2553-2559, 2006.

D. J. Mccoll, C. Chappey, N. T. Parkin, and M. D. Miller, Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database, Antivir Ther, vol.10, 2008.

C. Delaugerre, Barrière génétique à la résistance des antirétroviraux, Médecine Mal Infect, vol.40, pp.1-10, 2010.

J. Vingerhoets, L. Tambuyzer, H. Azijn, A. Hoogstoel, S. Nijs et al., Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies, AIDS, vol.24, pp.503-517, 2010.

A. Fun, A. M. Wensing, J. Verheyen, and M. Nijhuis, Human Immunodeficiency Virus gag and protease: partners in resistance, Retrovirology, vol.9, p.63, 2012.

S. D. Meyer, I. Dierynck, E. Lathouwers, B. V. Baelen, T. Vangeneugden et al., Phenotypic and genotypic determinants of resistance to darunavir: analysis of data from treatment

. Hiv-french-resistance, Algorithmes d'interprétation de la résistance des médicaments génotypiques VIH-1

C. Delaugerre, Résistance aux nouveaux antirétroviraux.HIV-1 resistance to new antiretroviral drugs

K. Anstett, B. Brenner, T. Mesplede, and M. A. Wainberg, HIV drug resistance against strand transfer integrase inhibitors, Retrovirology, vol.14, p.36, 2017.

D. A. Margolis, J. Gonzalez-garcia, H. Stellbrink, J. J. Eron, Y. Yazdanpanah et al., Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial, The Lancet, vol.390, pp.1499-510, 2017.

P. Cahn, A. L. Pozniak, H. Mingrone, A. Shuldyakov, C. Brites et al., Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study, The Lancet, vol.382, pp.700-708, 2013.

C. Charpentier and D. Descamps, Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations, Viruses, vol.18, 2018.

J. M. Kilby and J. J. Eron, Novel Therapies Based on Mechanisms of HIV-1 Cell Entry, N Engl J Med, vol.348, pp.2228-2266, 2003.

J. M. Llibre, J. M. Schapiro, and B. Clotet, Clinical Implications of Genotypic Resistance to the Newer Antiretroviral Drugs in HIV-1-Infected Patients with Virological Failure, Clin Infect Dis, vol.50, pp.872-81, 2010.

M. Lewis, J. Mori, J. Toma, M. Mosley, W. Huang et al., Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials, PloS One, vol.13, pp.240-99, 2018.

D. A. Cooper, R. T. Steigbigel, J. M. Gatell, J. K. Rockstroh, C. Katlama et al., Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

,

E. Todesco, Etude des variants résistants minoritaires aux antirétroviraux: impact sur la réponse virologique au traitement

A. Blanc, F. Bonnet, F. Brun-vezinet, D. Costagliola, F. Dabis et al., Groupe d'experts pour la prise en charge du VIH, p.41, 2017.

B. Clotet, N. Bellos, J. Molina, D. Cooper, J. Goffard et al., Efficacy and safety of darunavirritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials, The Lancet, vol.369, pp.1169-78, 2007.

M. W. Hull, J. S. Montaner, C. Katlama, R. Haubrich, and J. Lalezari, Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients: Evaluation of, Expert Opin Pharmacother, vol.23, pp.1433-1440, 2009.

A. Castagna, F. Maggiolo, G. Penco, D. Wright, A. Mills et al., Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir-and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study, J Infect Dis, vol.210, pp.354-62, 2014.

M. Santoro, C. Fornabiaio, M. Melena, L. Galli, A. Poli et al., Susceptibility to bictegravir in highly ARV-experienced patients after INSTI failure. CROI Conference

D. Sur,

Y. Yazdanpanah, C. Fagard, D. Descamps, A. M. Taburet, C. Colin et al., High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment-Experienced Patients Infected with Multidrug-Resistant HIV: Results of the ANRS 139 TRIO Trial, Clin Infect Dis, vol.49, pp.1441-1450, 2009.

R. T. Steigbigel, D. A. Cooper, H. Teppler, J. J. Eron, J. M. Gatell et al., Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials, Clin Infect Dis, vol.50, pp.605-617, 2010.

, EACS. Guidelines-9

A. Sáez-cirión, C. Bacchus, L. Hocqueloux, V. Avettand-fenoel, I. Girault et al., Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study, PLoS Pathog, 2013.

S. Lambert-niclot, P. Flandre, M. Valantin, G. Peytavin, C. Duvivier et al., Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy, J Infect Dis, vol.204, pp.1211-1217, 2011.

C. Katlama, Les bithérapies antirétrovirales

D. Sur,

A. C. Achhra, G. Mwasakifwa, J. Amin, and M. A. Boyd, Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and metaanalysis, Lancet HIV, vol.3, pp.351-60, 2016.

C. Katlama, L. Assoumou, M. Valantin, C. Soulié, E. Martinez et al., Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study, J Antimicrob Chemother, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02476360

L. Calza, E. Magistrelli, V. Colangeli, R. Manfredi, M. Borderi et al., Dual Raltegravir-Etravirine Combination as Maintenance Regimen in Virologically Suppressed HIV-1-Infected Patients, AIDS Res Hum Retroviruses, vol.33, pp.632-640, 2017.

J. M. Llibre, C. Hung, C. Brinson, F. Castelli, P. Girard et al., Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies, The Lancet, vol.391, pp.839-888, 2018.

V. Joly, C. Burdet, R. Landman, M. Vigan, C. Charpentier et al., Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL), J Antimicrob Chemother, vol.74, pp.739-784, 2019.

B. O. Taiwo, V. C. Marconi, B. Berzins, C. B. Moser, A. N. Nyaku et al., Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial, Clin Infect Dis. 17 mai, vol.66, issue.11, pp.1794-1801, 2018.

J. A. Perez-molina, R. Rubio, A. Rivero, J. Pasquau, I. Suárez-lozano et al., Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, openlabel, non-inferiority trial, Lancet Infect Dis, vol.15, pp.775-84, 2015.

J. R. Arribas, P. Girard, R. Landman, J. Pich, J. Mallolas et al., Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial, Lancet Infect Dis, vol.15, pp.785-92, 2015.

F. Pulido, E. Ribera, M. Lagarde, I. Pérez-valero, R. Palacios et al., Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial, Clin Infect Dis, vol.65, pp.2112-2120, 2017.

T. Nishijima, H. Gatanaga, T. Shimbo, H. Komatsu, T. Endo et al., Switching Tenofovir/Emtricitabine plus Lopinavir/r to Raltegravir plus Darunavir/r in Patients with Suppressed Viral Load Did Not Result in Improvement of Renal Function but Could Sustain Viral Suppression: A Randomized Multicenter Trial, PLoS One, vol.8, pp.736-775, 2013.

G. Madeddu, S. Rusconi, A. Cozzi-lepri, D. Giambenedetto, S. Bonora et al., Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ?50 cp/mL, For the Icona Foundation Study Group, vol.45, pp.521-529, 2017.

L. Calza, I. Danese, E. Magistrelli, V. Colangeli, R. Manfredi et al., Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors, HIV Clin Trials, vol.17, pp.38-47, 2016.

A. F. Capetti, M. V. Cossu, G. Orofino, G. Sterrantino, G. Cenderello et al., A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data, Disponible sur, vol.17

, Dual Therapy With Boosted Darunavir + Dolutegravir -Tabular View -ClinicalTrials.gov [Internet

S. Mathis, B. Khanlari, F. Pulido, M. Schechter, E. Negredo et al., Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis, PloS One, vol.6, pp.220-223, 2011.

C. Fagard, C. Colin, C. Charpentier, A. Rami, C. Jacomet et al., Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial, J Acquir Immune Defic Syndr, vol.59, pp.489-93, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00875207

A. M. Ebers, Y. Alkabab, B. Wispelwey, R. Dillingham, X. Wang et al., Efficacy of raltegravir, etravirine and darunavir/ritonavir for treatment-experienced HIV patients from a non-urban clinic population in the United States, Ther Adv Infect Dis, vol.4, pp.135-177, 2017.

C. Orkin, E. Dejesus, H. Khanlou, A. Stoehr, K. Supparatpinyo et al., Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatmentnaïve patients in the ARTEMIS trial, HIV Med, vol.14, pp.49-59, 2013.

A. Lazzarin, T. Campbell, B. Clotet, M. Johnson, C. Katlama et al., Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial, Lancet Lond Engl, vol.370, pp.39-48, 2007.

J. V. Madruga, P. Cahn, B. Grinsztejn, R. Haubrich, J. Lalezari et al., Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial, Lancet Lond Engl, vol.370, pp.29-38, 2007.

R. T. Steigbigel, M. Schechter, J. M. Gatell, A. Lazzarin, R. R. Rhodes et al., Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection, N Engl J Med, vol.16, 2008.

B. Grinsztejn, B. Nguyen, C. Katlama, J. M. Gatell, A. Lazzarin et al., Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial, Lancet Lond Engl, vol.369, pp.1261-1270, 2007.

C. Katlama, R. Esposito, J. M. Gatell, J. Goffard, B. Grinsztejn et al., Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1, AIDS Lond Engl, vol.21, pp.395-402, 2007.

C. Katlama, L. Assoumou, M. Valantin, C. Soulié, E. Martinez et al., Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study, J Antimicrob Chemother, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02476360

G. Madeddu, S. Rusconi, A. Cozzi-lepri, D. Giambenedetto, S. Bonora et al., Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ?50 cp/mL, Infection, vol.45, pp.521-529, 2017.

M. Valantin, L. Durand, M. Wirden, L. Assoumou, F. Caby et al., Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR study, J Antimicrob Chemother, vol.74, pp.2716-2738, 2019.

C. Charpentier, B. Roquebert, C. Colin, A. Taburet, C. Fagard et al., Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen, AIDS, vol.24, pp.2651-2657, 2010.

V. Potard, A. Canestri, S. Gallien, and D. Costagliola, French Hospital Database on HIV. Use of darunavir in HIV-1-infected individuals in routine clinical practice from 2012 to 2016 in France, J Antimicrob Chemother, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02291243

K. Andries, H. Azijn, T. Thielemans, D. Ludovici, M. Kukla et al., TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1, Antimicrob Agents Chemother, vol.48, pp.4680-4686, 2004.

A. Marcelin, P. Flandre, D. Descamps, L. Morand-joubert, C. Charpentier et al., Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitorexperienced HIV-1-infected patients, Antimicrob Agents Chemother, vol.54, pp.72-79, 2010.

, Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies, Lancet HIV, vol.4, pp.349-56, 2017.

D. Grover, A. Copas, H. Green, S. G. Edwards, D. T. Dunn et al., What is the risk of mortality following diagnosis of multidrug-resistant HIV-1?, J Antimicrob Chemother, vol.61, pp.705-718, 2008.